NASDAQ:ILMN

Illumina (ILMN) Stock Price, News & Analysis

$122.87
-1.59 (-1.28%)
(As of 04:28 PM ET)
Today's Range
$120.82
$124.74
50-Day Range
$116.69
$146.07
52-Week Range
$89.00
$228.13
Volume
1.23 million shs
Average Volume
1.74 million shs
Market Capitalization
$19.57 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$167.70

Illumina MarketRank™ Stock Analysis

Analyst Rating
Hold
2.32 Rating Score
Upside/​Downside
36.5% Upside
$167.70 Price Target
Short Interest
Healthy
3.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
0.78mentions of Illumina in the last 14 days
Based on 11 Articles This Week
Insider Trading
Acquiring Shares
$991,676 Bought Last Quarter
Proj. Earnings Growth
163.74%
From $0.91 to $2.40 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.59 out of 5 stars

Medical Sector

80th out of 909 stocks

Analytical Instruments Industry

3rd out of 27 stocks

ILMN stock logo

About Illumina Stock (NASDAQ:ILMN)

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

ILMN Stock Price History

ILMN Stock News Headlines

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Illumina, Inc. (ILMN)
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Illumina Appoints Ankur Dhingra CFO, Reaffirms Q1 And FY24 Outlook
Stocks Mixed Before Wednesday’s US CPI Report
See More Headlines
Receive ILMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/08/2024
Today
4/24/2024
Next Earnings (Confirmed)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:ILMN
CUSIP
45232710
Employees
9,300
Year Founded
1998

Price Target and Rating

Average Stock Price Target
$167.70
High Stock Price Target
$253.00
Low Stock Price Target
$100.00
Potential Upside/Downside
+35.7%
Consensus Rating
Hold
Rating Score (0-4)
2.32
Research Coverage
19 Analysts

Profitability

Net Income
$-1,161,000,000.00
Pretax Margin
-24.80%

Debt

Sales & Book Value

Annual Sales
$4.50 billion
Cash Flow
$3.68 per share
Book Value
$36.18 per share

Miscellaneous

Free Float
158,984,000
Market Cap
$19.68 billion
Optionable
Optionable
Beta
1.19

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Joydeep Goswami M.B.A. (Age 53)
    Ph.D., CFO, Chief Strategy & Corporate Development Officer
    Comp: $787.3k
  • Mr. Jacob Thaysen Ph.D. (Age 49)
    CEO & Director
  • Stephanie Campos
    President
  • Mr. Kevin Carl Pegels (Age 57)
    Chief of Global Operations
  • Mr. Scott Ericksen (Age 52)
    VP & Chief Accounting Officer
  • Dr. Steven Barnard Ph.D.
    Chief Technology Officer
  • Ms. Carissa L. Rollins (Age 54)
    Chief Information Officer
  • Ms. Sallilyn Schwartz
    Vice President of Investor Relations
  • Mr. Charles E. Dadswell Esq. (Age 65)
    Senior VP & General Counsel
    Comp: $1.06M
  • Ms. Kathryne Gambrell Reeves (Age 55)
    Chief Marketing Officer

Should I Buy Illumina Stock? ILMN Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Illumina, Inc.:

  • Illumina has a positive return on equity, indicating efficient use of shareholder funds to generate profits.
  • The company offers innovative sequencing and array-based solutions for genetic and genomic analysis, catering to a growing market demand for advanced genetic research tools.
  • Recent insider buying activity, such as CEO Jacob Thaysen purchasing shares, can signal confidence in the company's future prospects.
  • Illumina's revenue growth of 3.6% year-over-year demonstrates the company's ability to increase its top line despite market challenges.
  • With a 52-week high of $232.88, the stock has shown potential for strong price performance, attracting investors seeking capital appreciation.

Cons

Investors should be bearish about investing in Illumina, Inc. for these reasons:

  • Illumina's negative net margin of 25.78% may raise concerns about the company's profitability and cost management.
  • The stock ownership by institutional investors at 89.42% could lead to limited influence for individual retail investors in decision-making processes.
  • While revenue growth is positive, the company's earnings per share (EPS) of $0.14 for the quarter fell short of analysts' expectations, indicating potential volatility in financial performance.
  • Market analysts predict a lower EPS of 0.91 for the current year, suggesting potential challenges in meeting earnings targets and market expectations.
  • Investors should consider the competitive landscape in the life sciences tools & services industry, where Illumina operates, as it may impact the company's market position and growth prospects.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, April 11, 2024. Please send any questions or comments about these Illumina pros and cons to contact@marketbeat.com.

ILMN Stock Analysis - Frequently Asked Questions

Should I buy or sell Illumina stock right now?

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 2 sell ratings, 9 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View ILMN analyst ratings
or view top-rated stocks.

What is Illumina's stock price target for 2024?

19 Wall Street research analysts have issued 1-year price objectives for Illumina's shares. Their ILMN share price targets range from $100.00 to $253.00. On average, they expect the company's stock price to reach $167.70 in the next year. This suggests a possible upside of 36.5% from the stock's current price.
View analysts price targets for ILMN
or view top-rated stocks among Wall Street analysts.

How have ILMN shares performed in 2024?

Illumina's stock was trading at $139.24 at the start of the year. Since then, ILMN stock has decreased by 11.8% and is now trading at $122.87.
View the best growth stocks for 2024 here
.

When is Illumina's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ILMN earnings forecast
.

How can I listen to Illumina's earnings call?

Illumina will be holding an earnings conference call on Thursday, May 2nd at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) issued its quarterly earnings results on Thursday, February, 8th. The life sciences company reported $0.14 earnings per share for the quarter, topping analysts' consensus estimates of $0.01 by $0.13. The life sciences company had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.09 billion. Illumina had a positive trailing twelve-month return on equity of 2.20% and a negative net margin of 25.78%. The company's quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.14 earnings per share.
Read the conference call transcript
.

What guidance has Illumina issued on next quarter's earnings?

Illumina updated its FY 2024 earnings guidance on Tuesday, April, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $4.4 billion-$4.4 billion, compared to the consensus revenue estimate of $4.5 billion.

What is Francis deSouza's approval rating as Illumina's CEO?

496 employees have rated Illumina Chief Executive Officer Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among the company's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), PayPal (PYPL), Salesforce (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

Who are Illumina's major shareholders?

Illumina's stock is owned by a variety of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (0.24%), Raymond James & Associates (0.23%), Douglas Lane & Associates LLC (0.16%), Assenagon Asset Management S.A. (0.06%), CWM LLC (0.04%) and State of Michigan Retirement System (0.03%). Insiders that own company stock include Aimee L Hoyt, Alexander Aravanis, Charles Dadswell, Jacob Thaysen, Jay T Flatley, Phillip G Febbo, Susan H Tousi and Susan H Tousi.
View institutional ownership trends
.

How do I buy shares of Illumina?

Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Illumina have any subsidiaries?
The following companies are subsidiares of Illumina: Advanced Liquid Logic Inc., Affomix Corporation, BlueBee, BlueBee Belgium BVBA, BlueBee Holding BV, BlueGnome Ltd, BlueGnome Ltd., Conexio Genomics, Conexio Genomics Pty Ltd., Edico Genome, Emedgene Inc., Emedgene Technologies Ltd, Enancio, Enancio SAS, Epicentre Biotechnologies, GRAIL LLC, GenoLogics, Grail, Helixis, Illumina (China) Scientific Co Ltd, Illumina AB, Illumina Australia Pty. Ltd., Illumina Belgium BVBA, Illumina Brasil Produtos de Biotecnologia Ltda., Illumina Cambridge Ltd., Illumina Canada ULC, Illumina Denmark ApS, Illumina Finland Oy, Illumina France Sarl, Illumina GmbH, Illumina Hong Kong Limited, Illumina India Biotechnology Private Limited, Illumina Ireland Commercial Limited, Illumina Italy S.r.l., Illumina K.K. Japan, Illumina Korea Ltd., Illumina Netherlands B.V., Illumina New Zealand Limited, Illumina Norway AS, Illumina Productos de Espana S.L.U., Illumina Rus LLC, Illumina Shanghai (Trading) Co Ltd Beijing Branch, Illumina Shanghai (Trading) Co. Ltd., Illumina Singapore Pte. Ltd., Illumina Software Inc., Illumina Switzerland GmbH, Illumina US Manufacturing Operations Inc., Liquid Logic, Moleculo, NextBio, Solexa, Verinata Health, Verinata Health Inc., and thromboDx BV.
Read More
This page (NASDAQ:ILMN) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners